Ball lightning, a rare glowing orb seen during thunderstorms, has intrigued scientists for centuries. Learn what causes it, ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance ...

Exact Sciences Corp. reported performance data for its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at ...

Mizuho boosted American Tower Corporation AMT price target from $205 to $221. Mizuho analyst Vikram Malhorta maintained a ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $64.12 which represents a slight increase of $5.74 or 9.83% from the prior close of $58.38. The stock opened at $58.46 and ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its second quarter 2024 investor ...